Zacks: Brokerages Expect Lipocine Inc (LPCN) to Announce -$0.25 EPS
Wall Street brokerages predict that Lipocine Inc (NASDAQ:LPCN) will post earnings of ($0.25) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Lipocine’s earnings, with estimates ranging from ($0.28) to ($0.22). Lipocine reported earnings of ($0.22) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 13.6%. The firm is expected to issue its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Lipocine will report full year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($1.00) to ($0.62). For the next fiscal year, analysts expect that the firm will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.98) to $0.24. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Lipocine.
Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.10.
LPCN stock traded down $0.02 during midday trading on Tuesday, hitting $1.57. 60,300 shares of the company’s stock were exchanged, compared to its average volume of 364,387. The company has a quick ratio of 8.89, a current ratio of 8.89 and a debt-to-equity ratio of 0.62. Lipocine has a 12-month low of $1.03 and a 12-month high of $4.38. The company has a market capitalization of $33.17 million, a PE ratio of -1.50 and a beta of 0.48.
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Read More: Market Capitalization in the Stock Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.